Dr. Sander Houten,

Is a Clinical Biochemical Geneticist with over two decades of experience studying inborn errors of metabolism. For his doctoral studies, Dr. Houten focused on the isoprenoid and cholesterol biosynthesis pathway. He discovered that a deficiency of mevalonate kinase causes hyper-IgD syndrome, one of the periodic fever syndromes, and conducted studies to understand the consequences of this defect on cellular isoprenoid metabolism. As postdoctoral fellow, Dr. Houten studied mechanisms underlying the transcriptional control of metabolism in different mouse models. His research focused on signaling events elicited by metabolites and nuclear hormone receptors. He characterized metabolic effects of bile acids and defined a novel bile acid signaling pathway that affects energy homeostasis.

For his second postdoctoral fellowship, Dr. Houten combined his interest in regulation of metabolic processes and human genetics. He initiated a research line on mitochondrial fatty acid oxidation defects and was promoted to Principal Investigator. He applied state-of-the-art phenotyping methods to mouse models for mitochondrial fatty acid oxidation defects, which yielded new and unexpected insights in the pathophysiology of hypoglycemia and cardiac hypertrophy associated with these disorders. Dr. Houten is currently a tenured Associate Professor of Genetics and Genomic Sciences with the Icahn School of Medicine at Mount Sinai. He explores pathophysiological mechanisms in disorders of fatty acid oxidation and lysine degradation with the ultimate aim to develop new therapies.